Friday 21 June 2024

Optiscan Imaging (ASX:OIL) reveals next-gen microscopic medical imaging device

Optiscan Imaging (ASX:OIL) reveals its new microscopic medical imaging device, InVue™, which is designed to enable precision surgery by putting real-time digital pathology access directly into the hands of surgeons.

  • Optiscan reveals its InVue™ next-gen microscopic medical imaging device for precision surgery.
    • InVue™ expands Optiscan’s product portfolio into the surgical application market, representing a significant step forward in realising the Company’s strategic goals.
    • InVue™ can be used in a variety of clinical settings, most notably in cancer diagnosis and treatment.
    • InVue™ is designed to put digital pathology directly in the hands of surgeons as they operate, to enable on-the-spot decision making and treatment adjustments.

Optiscan CEO and Managing Director, Dr Camile Farah, said: “Getting our next-gen InVue™ microscopic medical imaging device to the reveal stage is a real credit to the hard work of the entire Optiscan team. The reveal is much more than just a significant milestone in the Company’s growth strategy. It paves the way for a significant evolution of digital pathology and precision surgery. InVue™ will bring digital pathology insights into the operating theatre and directly into the hands of surgeons. The end-result will be enhanced speed and accuracy of treatment, which should in turn deliver improved patient outcomes.”

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox